CRL
Charles River Laboratories International
Charles River Laboratories International insider trading
Every time one of CRL's executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.
SEC Form 4 data, Q3 2024 to Q2 2026
CRL insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 5 insiders traded CRL on the open market: 3 purchases worth $1.3M and 18 sales worth $9.3M, 9 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 1 purchase ($4.4K) and 3 sales ($251.6K), by one insider.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | +$4.4K1 buy | — | |
| Q4 2025 | — | — | |
| Q3 2025 | — | −$251.6K3 sales | |
| Q2 2025 | — | −$111.7K9 sales · 8 on a plan | |
| Q1 2025 | +$1.3M2 buys | −$715K1 sale | |
| Q4 2024 | — | −$1.6M3 sales | |
| Q3 2024 | — | −$6.6M2 sales · 1 on a plan |
- Largest purchase
- +$1M of CRL by Foster James C (Chairman, President and CEO · Director) on Feb 20, 2025.
- Largest sale
- −$6.3M of CRL by Foster James C (Chairman, President and CEO · Director) on Aug 01, 2024, under a 10b5-1 plan.
Open-market transactions through Jun 30, 2026most recent first
LaPlume Joseph W
EVP, Corp Strategy & Develop
+$4.4K
Mar 03, 2026
25 sh · $174.54
LaPlume Joseph W
EVP, Corp Strategy & Develop
−$65.5K
Aug 22, 2025
400 sh · $163.72
LaPlume Joseph W
EVP, Corp Strategy & Develop
−$126.1K
Aug 18, 2025
800 sh · $157.60
LaPlume Joseph W
EVP, Corp Strategy & Develop
−$60K
Aug 07, 2025
400 sh · $150.04
Massaro George10b5-1
Director
−$11.2K
May 15, 2025
81 sh · $137.68
Massaro George10b5-1
Director
−$4.8K
May 15, 2025
35 sh · $136.32
Massaro George10b5-1
Director
−$3.3K
May 15, 2025
24 sh · $139.05
Massaro George10b5-1
Director
−$12.7K
May 14, 2025
91 sh · $139.95
Massaro George10b5-1
Director
−$3K
May 14, 2025
21 sh · $140.78
Massaro George10b5-1
Director
−$2K
May 14, 2025
14 sh · $141.85
Massaro George10b5-1
Director
−$1K
May 14, 2025
7 sh · $145.54
Massaro George10b5-1
Director
−$1K
May 14, 2025
7 sh · $143.77
LaPlume Joseph W
EVP, Corp Strategy & Develop
−$72.7K
May 13, 2025
500 sh · $145.41
Foster James C
Chairman, President and CEO · Director
+$1M
Feb 20, 2025
6,075 sh · $165.01
LaPlume Joseph W
EVP, Corp Strategy & Develop
−$715K
Feb 20, 2025
4,400 sh · $162.50
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Mar 03, 2026 | LaPlume Joseph WEVP, Corp Strategy & Develop | 25 | $174.54 | +$4.4K |
| Aug 22, 2025 | LaPlume Joseph WEVP, Corp Strategy & Develop | 400 | $163.72 | −$65.5K |
| Aug 18, 2025 | LaPlume Joseph WEVP, Corp Strategy & Develop | 800 | $157.60 | −$126.1K |
| Aug 07, 2025 | LaPlume Joseph WEVP, Corp Strategy & Develop | 400 | $150.04 | −$60K |
| May 15, 2025 | Massaro George10b5-1Director | 81 | $137.68 | −$11.2K |
| May 15, 2025 | Massaro George10b5-1Director | 35 | $136.32 | −$4.8K |
| May 15, 2025 | Massaro George10b5-1Director | 24 | $139.05 | −$3.3K |
| May 14, 2025 | Massaro George10b5-1Director | 91 | $139.95 | −$12.7K |
| May 14, 2025 | Massaro George10b5-1Director | 21 | $140.78 | −$3K |
| May 14, 2025 | Massaro George10b5-1Director | 14 | $141.85 | −$2K |
| May 14, 2025 | Massaro George10b5-1Director | 7 | $145.54 | −$1K |
| May 14, 2025 | Massaro George10b5-1Director | 7 | $143.77 | −$1K |
| May 13, 2025 | LaPlume Joseph WEVP, Corp Strategy & Develop | 500 | $145.41 | −$72.7K |
| Feb 20, 2025 | Foster James CChairman, President and CEO · Director | 6,075 | $165.01 | +$1M |
| Feb 20, 2025 | LaPlume Joseph WEVP, Corp Strategy & Develop | 4,400 | $162.50 | −$715K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
After insiders bought CRL
What the stock actually did in the 90 days following each open-market purchase
Don't check CRL — let it ping you
Get told the moment an insider moves on CRL
Pro watches Charles River Laboratories International for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add CRL to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.
The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.
How to read CRL insider activity
- Open-market purchase (code P)
- An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
- Grants and option exercises (codes A, M)
- Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
- Cluster buy
- Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.
Other Health Care tickers
Questions
- How much CRL stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 5 Charles River Laboratories International insiders made 3 open-market purchases worth $1.3M and 18 sales worth $9.3M. 9 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 1 purchase ($4.4K) and 3 sales ($251.6K). The largest purchase was Foster James C buying $1M on Feb 20, 2025. The largest sale was Foster James C selling $6.3M on Aug 01, 2024.
- Where does CRL insider trading data come from?
- From the Form 4 filings Charles River Laboratories International's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.